Image

Asia-Pacific ELISpot and FluoroSpot Assay Market – Industry Trends and Forecast to 2028

  • Medical Devices
  • Published Report
  • Oct 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 122
  • No of Figures: 48
  • Medical Devices
  • Published Report
  • Oct 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 122
  • No of Figures: 48

Asia-Pacific ELISpot and FluoroSpot Assay Market, By Product Type (Assay Kits, Supplementary/ Ancillary Products, and Analyzers), Source (Human, Mouse, Monkey, and Others), Diseases (Infectious Diseases, Cancer, Autoimmune Diseases, Allergy, and Others) Application (Diagnostic Application, Research Applications), End-User (Hospitals and Clinical Laboratories, Research Institutes, Biopharmaceutical Companies, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (Japan,  China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific) Industry Trends and Forecast to 2028.

Asia Pacific ELISpot and FluoroSpot Assay Market

Market Analysis and Insights: Asia-Pacific ELISpot and FluoroSpot Assay Market  

Asia-Pacific ELISpot and FluoroSpot assay market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 15.5% in the forecast period of 2021 to 2028 and is expected to reach USD 191.28 million by 2028 from USD 59.02 million in 2020. The rising incidence of diabetes and growth of novel technological advancements for ELISpot and FluoroSpot assay is likely to be the major drivers which propel the demand of the market in the forecast period.

The enzyme-linked immunospot (ELISpot) assay is widely used in diagnosing various disease conditions due to its high sensitivity. They are very flexible and commonly used in measuring antigen-specific T cells in mice and humans. These tests are mostly preferred and highly popular lately due to their ability to measure a broad range of immune responses and cellular immune-related activities. Due to this, now ELISpot has been significantly converted from being a research tool to a widely used clinical assay in laboratories. The various form of ELISpot assays like IFN-gamma ELISpot, Granzyme B ELISpot, TGF-Beta 1 ELISpot, Fluorescent ELISpot, and others are in use for multiple diagnostic applications. The FluoroSpot assay works using the sandwich assay principle where a mixture of monoclonal antibodies with PVDF membranes is taken in a 96-well plate for assay. The ELISpot and FluoroSpot are widely suitable for secreted proteins, such as cytokines from activated cells. 

The increased incidence of chronic diseases, the surge in awareness about the timely diagnosis of the disease, and increased implementation of the FluoroSpot assay pave the way for the growth of ELISpot and FluoroSpot assay market.  Moreover, the growth potential in the emerging economies for ELISpot and FluoroSpot assay rise in healthcare expenditure bolsters the ELISpot and FluoroSpot assay market growth. However, the rise in cost, the less availability of the high-quality detection reagents, the ELISpot and FluoroSpot assay being inaccessible to developing countries are the restraints that can hinder the market growth. The operational barriers faced while conducting diagnostic tests, inconsistencies in the material used, and rising competition between market players are the challenges that can hinder market growth.

The Asia-Pacific ELISpot and FluoroSpot assay market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific ELISpot and FluoroSpot Assay MarketAsia-Pacific ELISpot and FluoroSpot Assay Market Scope and Market Size

THE ELISpot and FluoroSpot assay market is segmented on the basis of product type, source, diseases, applications, end-user, and distribution. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product type, the ELISpot and FluoroSpot assay market is segmented into assay kits, analyzers, supplementary or ancillary products. In 2021, the assay kits segment is expected to dominate the ELISpot and FluoroSpot assay market because of the growing preference for cell-based assays in drug discovery and the use of T-cell assays in cancer research.
  • On the basis of source, the ELISpot and FluoroSpot assay market is segmented into human, mouse, monkey, and others. In 2021, the human segment is expected to dominate the ELISpot and FluoroSpot assay market owing to the ease of detection of the cytokines in blood samples for the detection of chronic diseases.
  • On the basis of diseases, the ELISpot and FluoroSpot assay market is segmented into infectious diseases, cancer, autoimmune diseases, allergy, and others. In 2021, the infectious diseases segment is expected to dominate the ELISpot and FluoroSpot assay market because of the escalating number of chronic infectious diseases and increased emergence of contagious COVID-19 and high research activities targeted for rapid diagnostic applications.
  • On the basis of application, the ELISpot and FluoroSpot assay market is segmented into diagnostic and research applications. In 2021, the diagnostic application segment is expected to dominate the ELISpot and FluoroSpot assay market because of the escalating number of chronic infectious diseases and the use of point of care diagnostics during the pandemic.
  • On the basis of end-user, the ELISpot and FluoroSpot assay market is segmented into hospitals and clinics, research institutes, biopharmaceutical companies, and others. In 2021, the hospitals and clinics segment is expected to dominate the ELISpot and FluoroSpot assay market due to the availability of enhanced diagnostic infrastructure and healthcare insurance policies.
  • On the basis of distribution, the ELISpot and FluoroSpot assay market is segmented into direct tender and retail sales. In 2021, the direct tender segment is expected to dominate the ELISpot and FluoroSpot assay market due to the availability of more contacts, enhanced cost savings, and ensuring compliant engagements.

Asia-Pacific ELISpot and FluoroSpot Assay MarketAsia-Pacific ELISpot and FluoroSpot Assay Market Country Level Analysis

The Asia-Pacific ELISpot and FluoroSpot assay market is analysed, and market size information is provided by country, product type, source, diseases, applications, end-user, and distribution.

The countries covered in the ELISpot and FluoroSpot assay market report are Japan, China, India, South Korea, Australia, Singapore, Indonesia, Philippines, and rest of Asia-Pacific.

  • In Asia-Pacific, China is expected to grow with the highest CAGR in the forecasted periods as in the Asia-Pacific's countries, the demand for ELISpot and FluoroSpot assay products is increasing very rapidly with urbanization and laboratory automation. China is one of the leading countries to inculcate the ELISpot and FluoroSpot assay market.

Product segment in China is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of high number of market players. The Product segment in Japan is dominating the market owing to increasing technology development. India is growing due to rising healthcare expenditure.

The country section of the report also provides individual markets impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

The Growth Potential for ELIspot and Fluorospot Assay in Emerging Economies and the Strategic Initiatives by Market Players are Creating New Opportunities in the Asia-Pacific ELIspot and Fluorospot Assay Market 

 Asia-Pacific ELISpot and FluoroSpot assay Market also provides you with detailed market analysis for every country's growth in a particular industry with ELISpot and FluoroSpot assay sales, the impact of advancement in the ELISpot and FluoroSpot assay, and changes in regulatory scenarios with their support for the ELISpot and FluoroSpot assay market. The data is available for the historic period 2010 to 2019.

Competitive Landscape and Asia-Pacific ELISpot and FluoroSpot assay Market Share Analysis

 Asia-Pacific ELISpot and FluoroSpot assay market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to ELISpot and FluoroSpot assay market.

The major companies providing the Asia-Pacific ELISpot and FluoroSpot assay are. Oxford Immunotec USA, Inc., BD, R&D Systems, Inc., Mabtech, Thermo Fisher Scientific Inc., CellCarta, DIACLONE SAS, Abcam plc, Covance Inc., Cellular Technology Limited, U-CyTech, MIKROGEN DIAGNOSTIK, and Bio-Connect Diagnostics B.V among others.

DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players and new technological advancements for ELISpot and FluoroSpot assay are bridging the gap for chronic wounds treatment. 

For instance,

  • In April 2021, BD announced that the company would be presenting in virtual investor healthcare conferences "The Bank of America Securities 2021 Virtual Healthcare Conference" and "The UBS Global Healthcare Virtual Conference." This helped company in gaining more customers globally and improved revenue for the future market.

Collaboration, joint ventures, and other strategies by the market player is enhancing the company market in the ELISpot and FluoroSpot assay market, which also provides the benefit for the organization to improve their offering for ELISpot and FluoroSpot assay market.


SKU-
Why Choose Us


Frequently Asked Questions